# Helex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/helex

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.helex.bio
- Total disclosed funding: $3.5M
- Latest round: Seed (Oct 30, 2025)
- Investors on record: 3

## About

Based in New York, US, and founded in 2021 by Anirudh Nishtala, Rohini Kalvakuntla, and Poulami Chaudhuri (CEO), Helex Inc., d.b.a. Helex Bio, uses its proprietary genomics data, intelligent data-driven platform, and bioinformatics to design, validate and deliver therapy-specific gRNAs to businesses engaged in CRISPR-based genome editing therapeutics. In October 2025, Helex Inc. raised USD 3.5 million in seed funding led by new investor pi Ventures, with participation from another new investor? Bluehill Capital. Other unspecified and returning investor SOSV also participated in the round.

Helex provides an intelligent GPS for gene-editing, which is the solution for drug discovery and CRISPR-based cell and gene therapies. In addition, the company’s services include custom-engineered guide RNAs, custom-engineered cell lines, and proprietary bioinformatics pipelines for detailed analysis of CRISPR edits. The company will use the October 2025 funding to speed up preclinical development of its lead therapy for ADPKD and enhance its gene therapy platform.

## Funding rounds

- Seed, Oct 30, 2025, $3.5M — SOSV, pi Ventures, BlueHill Capital
- Seed, Aug 31, 2021 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- pi Ventures (https://capitalatlas.ai/funds/pi-ventures) — Seed
- BlueHill Capital (https://capitalatlas.ai/funds/bluehill-capital) — Seed